Partner Content Partner Content The 3rd Annual Blood-Brain Barrier Summit Returns in August ... Specialized Digital Conference for Biopharma
Events Partner Content 2nd Gene Therapy for Neurological Disorders Europe Maximising the Opportunity in CNS Gene Therapies
Views & Analysis Nine for 2021: Addressing the pandemic legacy In this second 'Nine for 2021' article, IQVIA’s Sarah Rickwood looks at four issues which will directly impact pharma in 2021: t
Views & Analysis Finding the big picture for Alzheimer’s The $4m Oskar Fischer Prize hopes to catalyse a breakthrough in Alzheimer’s research by encouraging a ‘big picture’ approach to th
Views & Analysis A bright future for CNS and Alzheimer's? Swiss biotech Asceneuron is developing what could be the first treatment for progressive supranuclear palsy (PSP), a rare CNS condition that can impair balance, movement, vision, and sp
Oncology LSX2026: Addressing adult eye cancer, with Roi Raz Roi Raz, CEO of ReBio Pharma, discusses injectable, bioresorbable sustained release delivery for ophthalmic therapeutics at LSX 2026.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
